1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6ADDD3CF4A40A71CB652584350028F002
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-factors-drive-results-biopharmaceutical-sales-training-programs-technology-trends-best-practices?opendocument
18
19opendocument
2018.206.48.142
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales Leadership Sales Training

Factors That Drive Results for Biopharmaceutical Sales Training Programs: Technology, Trends and Best Practices

ID: 5566


Features:

22 Info Graphics

9 Data Graphics

110+ Metrics

16 Narratives

50 Best Practices


Pages/Slides: 40


Published: 2019


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Factors That Drive Results for Biopharmaceutical Sales Training Programs: Technology, Trends and Best Practices”

STUDY OVERVIEW

As the biopharmaceutical landscape continues to evolve, the training of an organization's sales force plays an important role in its marketplace success. Forward-looking companies are keeping an eye on the emerging technologies and trends to boost the impact of their sales training programs.

Best Practices, LLC undertook this benchmarking research to provide pharmaceutical leaders with metrics and insights they can use to evaluate and compare the performance of their sales training organizations. In particular, this study identifies the successful technologies, emerging trends and best practices that drive effectiveness in high-performing sales training departments
within pharmaceutical and biotech companies.

KEY TOPICS

  • Technologies used to deliver training
  • Technology effectiveness
  • Best use, pros and cons of different types of training technology
  • Sales training issues for the year ahead
  • Best practices of benchmark participants for effective sales training

KEY METRICS

  • Indicate which of the listed applications of technology you are currently using or planning to deploy within the next year to deliver sales training
  • Please rate the effectiveness of each of the technologies you are currently using or planning to deploy within the next year for delivering or pushing out training and as a pull-through training tool
  • Approximately what percentage of your core training is delivered via the iPad and/or other similar mobile devices?
  • Please rate the level of attention you expect each of the listed issues to require from the Sales Training organization over the next 12 months

SAMPLE KEY FINDINGS

  • Training via mobile devices is gaining popularity: Learning management systems (LMS) with e-learning portals are mostly used by training departments. However, mobile devices deliveries are claimed to be more effective for pushing out sales training with nearly 80% of the companies either currently using or planning to deploy the technology within the next year.

METHODOLOGY

Best Practices, LLC engaged 56 sales training leaders from 36 pharmaceutical and biotech companies through a benchmarking survey. Research analysts also conducted six deep-dive executive interviews with selected benchmark participants. More than half of the benchmark participants serve at the director level and above.

Industries Profiled:
Biotech; Pharmaceutical; Medical Device; Manufacturing; Consumer Products; Diagnostic; Chemical; Health Care; Biopharmaceutical; Clinical Research; Laboratories; Professional Services


Companies Profiled:
Allergan; Arbor; Astellas; AstraZeneca; Avion Pharmaceuticals; LLC; Baxter Healthcare; Bayer; Biogen; Celgene; Dr Reddy's Laboratories; Eisai; Eli Lilly; EMD Serono; EryDel; Genentech; Grifols; Ipsen; Janssen; Jazz Pharmaceuticals; Johnson & Johnson; Lundbeck; Merck; Novartis; OTSUKA; Pernix Therapeutics; Pfizer; Sanofi; Shire; Strategic Outcomes; Sunovion; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Valeant; Verastem Oncology; Zydus Cadila

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.